PITTSBURGH--(BUSINESS WIRE)--invivodata® inc., the industry leader in electronic patient reported outcomes solutions for global clinical research, today announced that DiaryPRO®, its handheld electronic patient diary, was used to capture the primary endpoint data in a Phase II clinical study of Gabapentin GR™, an investigational extended-release tablet being developed by Depomed Inc. for the treatment of pain in patients with diabetic peripheral neuropathy (DPN), a nerve disorder caused by diabetes.
